Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects
Brief Summary: The primary objective of this study was to evaluate the effect of 24 weeks of evolocumab administered subcutaneously (SC) every month, compared with ezetimibe, on low-density lipoprotein cholesterol (LDL-C) levels in adults with high cholesterol who are unable to tolerate an effective dose of a statin due to muscle-related side effects (MRSE).


Options:
A: Arm Label: Part A: Atorvastatin 20 mg => Placebo; Type: OTHER; Interventions: Drug: Atorvastatin, Drug: Placebo to Atorvastatin | Arm Label: Part A: Placebo => Atorvastatin 20 mg; Type: OTHER; Interventions: Drug: Atorvastatin, Drug: Placebo to Atorvastatin | Arm Label: Part B: Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Other: Placebo to Evolocumab | Arm Label: Part B: Evolocumab; Type: EXPERIMENTAL; Interventions: Other: Placebo to Ezetimibe, Drug: Evolocumab | Arm Label: Part C: Open-label Evolocumab; Type: EXPERIMENTAL; Interventions: Drug: Evolocumab | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Part A: Atorvastatin 20 mg => Placebo, Part A: Placebo => Atorvastatin 20 mg | Intervention Type: DRUG; Name: Placebo to Atorvastatin; Assigned to Arm(s): Part A: Atorvastatin 20 mg => Placebo, Part A: Placebo => Atorvastatin 20 mg | Intervention Type: OTHER; Name: Placebo to Ezetimibe; Assigned to Arm(s): Part B: Evolocumab | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Part B: Ezetimibe | Intervention Type: OTHER; Name: Placebo to Evolocumab; Assigned to Arm(s): Part B: Ezetimibe | Intervention Type: DRUG; Name: Evolocumab; Assigned to Arm(s): Part B: Evolocumab, Part C: Open-label Evolocumab
B: Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Drug: Placebo (for Alirocumab) | Arm Label: Alirocumab 75/Up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for Ezetimibe) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75/Up to 150 mg Q2W | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for Alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for Ezetimibe); Assigned to Arm(s): Alirocumab 75/Up to 150 mg Q2W
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Intervention Type: DRUG; Name: REGN727; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: cohort 3; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: cohort 4; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: cohort 5; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Intervention Type: DRUG; Name: REGN727; Assigned to Arm(s): Cohort 1, Cohort 2, cohort 3, cohort 4, cohort 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, cohort 3, cohort 4, cohort 5

Answer: A